• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    5/8/24 8:06:34 AM ET
    $CLOV
    $COCH
    $CVM
    $ENVB
    Medical Specialities
    Health Care
    Industrial Specialties
    Health Care
    Get the next $CLOV alert in real time by email

    Gainers

    • Repare Therapeutics (NASDAQ:RPTX) shares rose 34.1% to $4.4 during Wednesday's pre-market session. The company's market cap stands at $186.7 million. The company's, Q1 earnings came out yesterday.
    • Enveric Biosciences (NASDAQ:ENVB) shares increased by 16.85% to $1.04. The company's market cap stands at $7.5 million.
    • Clover Health Investments (NASDAQ:CLOV) stock increased by 16.21% to $0.86. The company's market cap stands at $426.3 million. As per the press release, Q1 earnings came out yesterday.
    • Envoy Medical (NASDAQ:COCH) stock rose 13.88% to $3.28. The company's market cap stands at $64.2 million.
    • Myriad Genetics (NASDAQ:MYGN) stock moved upwards by 13.75% to $22.5. The market value of their outstanding shares is at $2.0 billion. As per the press release, Q1 earnings came out yesterday.
    • CEL-SCI (AMEX:CVM) stock increased by 13.1% to $1.89. The market value of their outstanding shares is at $101.9 million.

    Losers

    • Treace Medical Concepts (NASDAQ:TMCI) shares fell 58.5% to $4.61 during Wednesday's pre-market session. The market value of their outstanding shares is at $285.5 million. As per the news, the Q1 earnings report came out yesterday.
    • Inspire Medical Systems (NYSE:INSP) shares fell 16.85% to $204.25. The market value of their outstanding shares is at $6.1 billion. As per the press release, Q1 earnings came out yesterday.
    • Immuron (NASDAQ:IMRN) shares fell 13.15% to $2.18. The market value of their outstanding shares is at $12.4 million.
    • Semler Scientific (NASDAQ:SMLR) stock decreased by 12.69% to $24.58. The market value of their outstanding shares is at $172.8 million. As per the news, the Q1 earnings report came out yesterday.
    • Nuwellis (NASDAQ:NUWE) stock decreased by 9.91% to $0.24. The company's market cap stands at $3.6 million. The company's, Q1 earnings came out yesterday.
    • OPKO Health (NASDAQ:OPK) shares decreased by 9.24% to $1.18. The market value of their outstanding shares is at $822.4 million. As per the press release, Q1 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CLOV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLOV
    $COCH
    $CVM
    $ENVB

    CompanyDatePrice TargetRatingAnalyst
    Inspire Medical Systems Inc.
    $INSP
    2/13/2026Outperform → Peer Perform
    Wolfe Research
    Inspire Medical Systems Inc.
    $INSP
    2/12/2026$74.00Outperform → Neutral
    Robert W. Baird
    Inspire Medical Systems Inc.
    $INSP
    2/12/2026$70.00Overweight → Equal Weight
    Wells Fargo
    Inspire Medical Systems Inc.
    $INSP
    1/27/2026$90.00Outperform → Sector Perform
    RBC Capital Mkts
    Inspire Medical Systems Inc.
    $INSP
    1/22/2026$96.00Buy → Hold
    Truist
    Inspire Medical Systems Inc.
    $INSP
    1/22/2026Outperform → Perform
    Oppenheimer
    Inspire Medical Systems Inc.
    $INSP
    12/8/2025$175.00Perform → Outperform
    Oppenheimer
    Inspire Medical Systems Inc.
    $INSP
    12/2/2025$130.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $CLOV
    $COCH
    $CVM
    $ENVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Raha Samraat S. bought $199,844 worth of shares (40,000 units at $5.00), increasing direct ownership by 9% to 493,104 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    3/9/26 7:03:13 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Phanstiel S. Louise bought $494,722 worth of shares (104,507 units at $4.73), increasing direct ownership by 59% to 281,951 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    2/27/26 4:46:18 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Patel Mona Chetan bought $125,000 worth of shares (312,500 units at $0.40), increasing direct ownership by 1,562% to 332,500 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:51:51 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $CLOV
    $COCH
    $CVM
    $ENVB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 21, 2023 - FDA Roundup: March 21, 2023

    For Immediate Release: March 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA completed its second pre-market consultation for a human food made from cultured animal cells. The firm will use animal cell culture technology to take living cells from chickens and grow the cells in a controlled environment to make the cultured

    3/21/23 3:12:46 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $CLOV
    $COCH
    $CVM
    $ENVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Treace John T. covered exercise/tax liability with 7,083 shares, decreasing direct ownership by 0.10% to 7,004,550 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    3/11/26 9:00:04 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Hair Mark covered exercise/tax liability with 4,659 shares, decreasing direct ownership by 0.54% to 863,549 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    3/11/26 9:00:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Chief Legl & Comp Off, CorpSec Elder Scot Michael covered exercise/tax liability with 1,850 shares, decreasing direct ownership by 0.23% to 794,936 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    3/11/26 9:00:07 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $CLOV
    $COCH
    $CVM
    $ENVB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Envoy Medical Completes Enrollment of Pivotal Clinical Trial Evaluating First-Of-Its-Kind Fully Implanted Cochlear Implant

    First Cochlear Implant Company to Announce Completed Enrollment of a U.S. Pivotal Clinical Trial for a Fully Implanted Cochlear Implant seeking FDA ApprovalWhite Bear Lake, Minnesota--(Newsfile Corp. - March 11, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced completed enrollment of its pivotal clinical trial for the investigational fully implanted Acclaim® cochlear implant. With the successful implantation of the 56th and final patient, Envoy Medical is the first cochlear implant company to achieve full enrollment of a U.S. pivotal clinical trial to evaluate a fully implanted

    3/11/26 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    UPDATED – Moving from Pledge to Production, Clover Health is Now Live on Kno2, Participating in Recently Announced Federal Interoperability Initiatives

    NOTICE: This is an updated version of a press release originally issued March 4, 2026 by Clover Health Investments, Corp. (NASDAQ:CLOV). Language has been updated to further refine the description of Clover Health's participation in federal interoperability initiatives. WILMINGTON, Del., March 10, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, and Kno2, healthcare's leading communication network, today announced a collaboration enabling Clover Health to be live on a network that is participating in interoperability

    3/10/26 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4.Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter.Closed a $5.0 million private p

    3/10/26 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CLOV
    $COCH
    $CVM
    $ENVB
    SEC Filings

    View All

    SEC Form 10-K filed by Nuwellis Inc.

    10-K - Nuwellis, Inc. (0001506492) (Filer)

    3/11/26 5:24:35 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Nuwellis, Inc. (0001506492) (Filer)

    3/10/26 4:02:58 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form PRE 14A filed by Inspire Medical Systems Inc.

    PRE 14A - Inspire Medical Systems, Inc. (0001609550) (Filer)

    3/9/26 4:37:45 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $CLOV
    $COCH
    $CVM
    $ENVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Inspire Medical Systems downgraded by Wolfe Research

    Wolfe Research downgraded Inspire Medical Systems from Outperform to Peer Perform

    2/13/26 8:29:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Inspire Medical Systems from Outperform to Neutral and set a new price target of $74.00

    2/12/26 7:22:54 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Inspire Medical Systems from Overweight to Equal Weight and set a new price target of $70.00

    2/12/26 7:22:44 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $CLOV
    $COCH
    $CVM
    $ENVB
    Leadership Updates

    Live Leadership Updates

    View All

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CLOV
    $COCH
    $CVM
    $ENVB
    Financials

    Live finance-specific insights

    View All

    Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4.Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter.Closed a $5.0 million private p

    3/10/26 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results

    PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the fourth quarter and full-year ended December 31, 2025. Recent Highlights Generated revenue of $62.5 million in fourth quarter 2025 and revenue of $212.7 million for the full-year 2025, an increase of 2% compared to the prior year.Reported fourth quarter 2025 net loss of $(9.4) million and adjusted EBITDA of $6.2 million in the fourth quarter 2025. Reported full-year 2025 net loss of $(59.0) million c

    2/27/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Clover Health Reports Fourth Quarter & Full Year 2025 Results; Provides Full Year 2026 Guidance

    Business Highlights: Generated full year 2025 Adjusted EBITDA profitability while growing membership by 38% and Insurance revenue by 41% year-over-yearAchieved industry-leading 2026 AEP growth of 53% year-over-year with strong returning member retentionExpect improving cohort economics powered by Clover Assistant to drive our first-ever full year of GAAP Net Income profitability in 2026 Financial Results: Full year 2025 Medicare Advantage membership of 113,803, up 38% year-over-yearFull year 2025 Total revenues of $1.9 billion, up 40% year-over-yearFull year 2025 GAAP Net loss of $86 million, Adjusted EBITDA of $22 million, and Adjusted Net Income of $20 million Full Year 2026 Gu

    2/26/26 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    $COCH
    $CVM
    $ENVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Semler Scientific Inc.

    SC 13D/A - Semler Scientific, Inc. (0001554859) (Subject)

    12/12/24 4:16:00 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Semler Scientific Inc.

    SC 13G - Semler Scientific, Inc. (0001554859) (Subject)

    11/26/24 12:09:40 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by OPKO Health Inc.

    SC 13D/A - OPKO HEALTH, INC. (0000944809) (Subject)

    11/15/24 4:39:33 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLOV
    $COCH
    $CVM
    $ENVB
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Financial Insight: Purchase at Clover Health Investments Corp. on Jun 20

    The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso

    6/20/24 6:36:05 PM ET
    $CLOV
    Medical Specialities
    Health Care